USP17L7
gene geneOn this page
Summary
USP17L7 (ubiquitin specific peptidase 17 like family member 7, HGNC:37180) is a protein-coding gene on chromosome 8p23.1, encoding Inactive ubiquitin carboxyl-terminal hydrolase 17-like protein 7 (P0C7H9).
Predicted to enable cysteine-type deubiquitinase activity. Predicted to be involved in regulation of apoptotic process and regulation of protein stability. Predicted to be located in endoplasmic reticulum. Predicted to be active in cytosol and nucleus.
Source: NCBI Gene 392197 — RefSeq curated summary.
At a glance
- MANE Select transcript:
NM_001256869
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:37180 |
| Approved symbol | USP17L7 |
| Name | ubiquitin specific peptidase 17 like family member 7 |
| Location | 8p23.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000226430 |
| Ensembl biotype | protein_coding |
| Entrez | 392197 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000530447
RefSeq mRNA: 1 — MANE Select: NM_001256869
NM_001256869
CCDS: CCDS78305
Canonical transcript exons
ENST00000530447 — 1 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002180313 | 12132417 | 12134099 |
Expression profiles
Bgee: expression breadth tissue_specific, 4 present calls, max score 63.83.
Top tissues by expression
110 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| sural nerve | UBERON:0015488 | 63.83 | silver quality |
| colonic epithelium | UBERON:0000397 | 46.14 | gold quality |
| corpus callosum | UBERON:0002336 | 42.78 | silver quality |
| bone marrow cell | CL:0002092 | 42.53 | gold quality |
| stromal cell of endometrium | CL:0002255 | 40.11 | gold quality |
| adrenal tissue | UBERON:0018303 | 39.77 | silver quality |
| skeletal muscle tissue | UBERON:0001134 | 38.74 | gold quality |
| ganglionic eminence | UBERON:0004023 | 37.37 | gold quality |
| ventricular zone | UBERON:0003053 | 36.48 | gold quality |
| cortical plate | UBERON:0005343 | 36.47 | gold quality |
| muscle tissue | UBERON:0002385 | 36.38 | gold quality |
| urinary bladder | UBERON:0001255 | 35.87 | gold quality |
| tonsil | UBERON:0002372 | 35.31 | gold quality |
| bone marrow | UBERON:0002371 | 35.00 | gold quality |
| primary visual cortex | UBERON:0002436 | 34.25 | gold quality |
| mucosa of stomach | UBERON:0001199 | 34.11 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 33.64 | gold quality |
| right uterine tube | UBERON:0001302 | 33.49 | gold quality |
| cerebellum | UBERON:0002037 | 33.16 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 33.01 | gold quality |
| cerebellar cortex | UBERON:0002129 | 32.95 | gold quality |
| monocyte | CL:0000576 | 32.85 | gold quality |
| left ovary | UBERON:0002119 | 32.67 | gold quality |
| uterine cervix | UBERON:0000002 | 32.59 | gold quality |
| leukocyte | CL:0000738 | 32.37 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 32.15 | gold quality |
| right lung | UBERON:0002167 | 31.62 | gold quality |
| liver | UBERON:0002107 | 30.57 | gold quality |
| caudate nucleus | UBERON:0001873 | 30.13 | silver quality |
| prefrontal cortex | UBERON:0000451 | 30.11 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 0.32 |
Regulation
Is transcription factor: no
Cross-species orthologs
0 orthologs
Paralogs (71): USP2 (ENSG00000036672), USP28 (ENSG00000048028), USP36 (ENSG00000055483), USP13 (ENSG00000058056), USP33 (ENSG00000077254), USP40 (ENSG00000085982), USP48 (ENSG00000090686), USP14 (ENSG00000101557), USP11 (ENSG00000102226), USP10 (ENSG00000103194), USP31 (ENSG00000103404), USP42 (ENSG00000106346), USP5 (ENSG00000111667), USP4 (ENSG00000114316), USP9Y (ENSG00000114374), USP34 (ENSG00000115464), USP35 (ENSG00000118369), USP45 (ENSG00000123552), USP22 (ENSG00000124422), USP9X (ENSG00000124486), USP6 (ENSG00000129204), USP29 (ENSG00000131864), USP26 (ENSG00000134588), USP30 (ENSG00000135093), USP15 (ENSG00000135655), USP37 (ENSG00000135913), USP44 (ENSG00000136014), USP20 (ENSG00000136878), USP8 (ENSG00000138592), USP3 (ENSG00000140455), USP21 (ENSG00000143258), USP43 (ENSG00000154914), USP25 (ENSG00000155313), USP16 (ENSG00000156256), USP24 (ENSG00000162402), USP1 (ENSG00000162607), USP49 (ENSG00000164663), USP38 (ENSG00000170185), USP50 (ENSG00000170236), USP47 (ENSG00000170242)
Protein
Protein identifiers
Inactive ubiquitin carboxyl-terminal hydrolase 17-like protein 7 — P0C7H9 (reviewed: P0C7H9)
All UniProt accessions (1): P0C7H9
UniProt curated annotations — full annotation on UniProt →
Subcellular location. Nucleus. Endoplasmic reticulum.
Similarity. Belongs to the peptidase C19 family. USP17 subfamily.
RefSeq proteins (1): NP_001243798* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001394 | Peptidase_C19_UCH | Domain |
| IPR018200 | USP_CS | Conserved_site |
| IPR028889 | USP | Domain |
| IPR038765 | Papain-like_cys_pep_sf | Homologous_superfamily |
| IPR050164 | Peptidase_C19 | Family |
Pfam: PF00443
UniProt features (10 total): region of interest 3, compositionally biased region 3, sequence variant 2, chain 1, domain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P0C7H9-F1 | 66.75 | 0.40 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 12 (showing top):
GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_REMOVAL, GOMF_CYSTEINE_TYPE_PEPTIDASE_ACTIVITY, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_REGULATION_OF_PROTEIN_STABILITY, GOBP_PROTEOLYSIS, GOMF_PEPTIDASE_ACTIVITY, GOMF_UBIQUITIN_LIKE_PROTEIN_PEPTIDASE_ACTIVITY, PAX7_TARGET_GENES, GOBP_REGULATION_OF_PROGRAMMED_CELL_DEATH, GOBP_PROTEIN_MODIFICATION_PROCESS, GOMF_DEUBIQUITINASE_ACTIVITY, chr8p23
GO Biological Process (4): proteolysis (GO:0006508), protein deubiquitination (GO:0016579), regulation of protein stability (GO:0031647), regulation of apoptotic process (GO:0042981)
GO Molecular Function (1): cysteine-type deubiquitinase activity (GO:0004843)
GO Cellular Component (3): nucleus (GO:0005634), endoplasmic reticulum (GO:0005783), cytosol (GO:0005829)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| intracellular membrane-bounded organelle | 2 |
| cytoplasm | 2 |
| protein metabolic process | 1 |
| cysteine-type deubiquitinase activity | 1 |
| protein modification by small protein removal | 1 |
| regulation of biological quality | 1 |
| apoptotic process | 1 |
| regulation of programmed cell death | 1 |
| cysteine-type peptidase activity | 1 |
| deubiquitinase activity | 1 |
| endomembrane system | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
82 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| USP17L7 | FAM90A10 | A6NDY2 | 720 |
| USP17L7 | DEFB108B | Q8NET1 | 579 |
| USP17L7 | DEFB107A | Q8IZN7 | 573 |
| USP17L7 | DEFB106A | Q8N104 | 505 |
| USP17L7 | DEFB105A | Q8NG35 | 491 |
| USP17L7 | PIP5KL1 | Q5T9C9 | 448 |
| USP17L7 | PRR23B | Q6ZRT6 | 447 |
| USP17L7 | PRR23A | A6NEV1 | 446 |
| USP17L7 | PRR23D1 | E9PI22 | 446 |
| USP17L7 | TMEM117 | Q9H0C3 | 445 |
| USP17L7 | A0A0G2JN59 | A0A0G2JN59 | 418 |
| USP17L7 | PRR23C | Q6ZRP0 | 391 |
| USP17L7 | USP53 | Q70EK8 | 382 |
| USP17L7 | MIA2 | Q96PC5 | 323 |
| USP17L7 | ARSD | P51689 | 306 |
IntAct
4 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| USP17L7 | USP26 | psi-mi:“MI:0915”(physical association) | 0.400 |
| USP17L24 | USP17L7 | psi-mi:“MI:0914”(association) | 0.350 |
| USP17L2 | USP17L7 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (6): USP17L7 (Affinity Capture-MS), USP17L7 (Affinity Capture-MS), ZKSCAN4 (Cross-Linking-MS (XL-MS)), USP17L7 (Affinity Capture-MS), USP17L7 (Affinity Capture-MS), USP17L7 (Affinity Capture-MS)
ESM2 similar proteins: A2A5N8, A6NCW0, A6NCW7, A8MUK1, B1AQJ2, B2RQC2, C9J2P7, C9JJH3, C9JLJ4, C9JPN9, C9JVI0, D3ZWK4, D6R901, D6R9N7, D6RA61, D6RBM5, D6RBQ6, D6RCP7, D6RJB6, E9Q9U0, G5E8G2, G5E8I7, O94966, P0C7H9, P0C7I0, P35125, P51784, Q0E2F9, Q0WX57, Q2TAC6, Q3UJD6, Q4KLL9, Q5R7G8, Q5TKR9, Q61068, Q66HE5, Q6J1Y9, Q6PFD6, Q6QN14, Q6R6M4
Diamond homologs: A1L1K8, A6NCW0, A6NCW7, A8MUK1, C9J2P7, C9JJH3, C9JLJ4, C9JPN9, C9JVI0, D6R901, D6R9N7, D6RA61, D6RBQ6, D6RCP7, D6RJB6, G1SW77, P0C7H9, P0C7I0, Q0WX57, Q5JVS0, Q5XJA5, Q6AXS5, Q6NRY1, Q6PB22, Q6R6M4, Q7RTZ2, Q8NC51, Q9CY58, Q9I9R0, Q9JKS5, B1AQJ2, B2RQC2, B3M3M6, B3NC86, B4HUI5, B4IXE0, B4KXJ5, B4LG38, B4MLR8, B4PIW8
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
0 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 0 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
22 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 8:12134016:C:CT | acceptor_gain | 0.4400 |
| 8:12133937:GCC:G | acceptor_gain | 0.3700 |
| 8:12133801:A:AC | donor_gain | 0.3400 |
| 8:12133814:C:CA | donor_gain | 0.3300 |
| 8:12133938:C:A | acceptor_gain | 0.3200 |
| 8:12133935:TA:T | acceptor_gain | 0.3100 |
| 8:12134050:C:CT | acceptor_gain | 0.2900 |
| 8:12133722:C:CC | acceptor_gain | 0.2800 |
| 8:12133802:G:C | donor_gain | 0.2800 |
| 8:12133936:AGC:A | acceptor_gain | 0.2800 |
| 8:12134075:C:G | acceptor_gain | 0.2700 |
| 8:12133740:A:AT | acceptor_gain | 0.2400 |
| 8:12133741:T:TT | acceptor_gain | 0.2400 |
| 8:12133721:A:AC | acceptor_gain | 0.2300 |
| 8:12134016:C:T | acceptor_gain | 0.2300 |
| 8:12132792:T:A | donor_gain | 0.2200 |
| 8:12132892:A:C | acceptor_gain | 0.2200 |
| 8:12133506:A:T | acceptor_gain | 0.2200 |
| 8:12134077:T:G | acceptor_gain | 0.2200 |
| 8:12132892:A:AC | acceptor_gain | 0.2100 |
| 8:12132883:CTCTT:C | acceptor_gain | 0.2000 |
| 8:12132888:C:CC | acceptor_gain | 0.2000 |
AlphaMissense
3498 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 8:12133518:A:C | F164L | 0.851 |
| 8:12133518:A:T | F164L | 0.851 |
| 8:12133520:A:G | F164L | 0.851 |
| 8:12133161:G:C | F283L | 0.811 |
| 8:12133161:G:T | F283L | 0.811 |
| 8:12133163:A:G | F283L | 0.811 |
| 8:12133551:G:C | F153L | 0.772 |
| 8:12133551:G:T | F153L | 0.772 |
| 8:12133553:A:G | F153L | 0.772 |
| 8:12132897:A:C | F371L | 0.740 |
| 8:12132897:A:T | F371L | 0.740 |
| 8:12132899:A:G | F371L | 0.740 |
| 8:12133509:A:C | F167L | 0.738 |
| 8:12133509:A:T | F167L | 0.738 |
| 8:12133511:A:G | F167L | 0.738 |
| 8:12133419:A:C | F197L | 0.725 |
| 8:12133419:A:T | F197L | 0.725 |
| 8:12133421:A:G | F197L | 0.725 |
| 8:12132974:A:G | W346R | 0.614 |
| 8:12132974:A:T | W346R | 0.614 |
| 8:12133968:G:C | F14L | 0.565 |
| 8:12133968:G:T | F14L | 0.565 |
| 8:12133970:A:G | F14L | 0.565 |
dbSNP variants (sampled 300 via entrez): RS1001819009 (8:7337154 T>C), RS1002084764 (8:7336761 C>G,T), RS1003898352 (8:7335661 T>C), RS1005657151 (8:7338314 C>G), RS1006041695 (8:7338951 G>A), RS1006694004 (8:12132654 G>A), RS1007747066 (8:7335975 G>A), RS1011227128 (8:12134667 C>A), RS1011427817 (8:12135932 C>T), RS1011825312 (8:7336616 GA>G), RS1012879915 (8:7335558 C>T), RS1017268571 (8:7335985 G>A,T), RS1017737846 (8:7336257 C>G,T), RS1018325854 (8:7338968 G>A), RS1021219219 (8:12134703 A>G,T)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
4 total (human), top 4 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | increases expression | 1 |
| pentanal | increases expression | 1 |
| abrine | increases expression | 1 |
| Thiram | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.